Celyad Sa Stock News

The U.S. Food and Drug Administration placed a clinical hold on Celyad Oncology''s (CYAD) phase 1b trial, dubbed CYAD-101-002 (KEYNOTE-B79), due to insufficient information to assess…

Celyad Oncology SA (NASDAQ: CYAD ) has decided to voluntarily pause the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, a part of a collaboration with Merck & Co Inc (NYSE: MRK ). The trial is evaluating the company''s CYAD-101 administered concurrently with FOLFOX chemotherapy, … Full story available on Benzinga.com

Celyad Oncology (CYAD) voluntarily paused its CYAD-101-002 (KEYNOTE-B79) phase 1b trial (NCT04991948) in colorectal cancer, after it received reports of two fatalities that presented…

MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric

The stock price of Celyad Oncology (NASDAQ: CYAD) increased by over 6% pre-market today. This is why it happened.

Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) ("Celyad" or the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chime

Trading penny stocks right now? Consider these three tips and tricks The post How to Make Money With Penny Stocks And the Omicron Variant appeared first on Penny Stocks to Buy, Picks, News and Informa

Celyad Oncology SA (NASDAQ: CYAD ) has announced a private placement worth $32.5 million (about 28.7 million) with Fortress Investment Group . The offering includes the private placement of 6.5 million shares and will close by December 8. Celyad will issue shares at $5.00 (about 4.42) per share, representing an 18.5% premium to the 30-day volume-weighted average price. The offer price represents a whopping 40% Full story available on Benzinga.com

Regulatory News: Celyad Oncology SA (Euronext Nasdaq:CYAD) ("Celyad" or the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor

MONT-SAINT-GUIBERT, Belgium, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Celyad or the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has entered into a subscription agreement with an affiliate of Fortress Investment Group (such affiliate Fortress) for the private placement of 6,500,000 ordinary shares for gross proceeds of USD 32.5 million (about EUR 28.7 million). The subscription will take place within the framework of the authorized capital and it is expected to close on or about December 8, 2021, subject to satisfaction of customary closing conditions.

Two abstracts will be presented in a pre-recorded poster presentation and oral session Two abstracts will be presented in a pre-recorded poster presentation and oral session

MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric